FDA approves Travere's Filspari as first drug for the kidney disease called FSGS
Nicole DeFeudis / endpoints - The FDA expanded the label for Filspari on Monday to add another kidney condition. The drug is now the first therapy approved in the US for focal segmental glomerulosclerosis (FSGS). The pill may be taken ...
AI Summary: The FDA approved Filspari for focal segmental glomerulosclerosis (FSGS), delivering the first specifically authorized treatment for this rare kidney disease. The approval provides a targeted therapeutic option for patients and marks a commercial milestone for Travere, raising hopes for better outcomes while spotlighting questions about access, pricing, and long‑term real‑world effectiveness.
Related Stories
FDA again rejects Aldeyra’s dry‑eye drug for weak evidence / 5 months
Orca Bio allogeneic cell therapy wins landmark FDA approval / 1 month
FDA approves Merck’s once‑daily two‑drug HIV pill, shaking up market / 4 months
FDA clears first oral cholesterol pill to compete with injections / 6 wks
BioMarin Phase 3 failure dims hopes for rare‑disease therapy / 3 months
Insmed shelves Brinsupri in skin indication after mid‑stage flop / 4 months
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Price Transparency, Research Funding, Novo Nordisk, Medical Devices and look for the RSS link.
StackHealth Time Machine